G

GemPharmatech Co Ltd
SSE:688046

Watchlist Manager
GemPharmatech Co Ltd
SSE:688046
Watchlist
Price: 13.35 CNY -2.55%
Market Cap: 5.5B CNY
Have any thoughts about
GemPharmatech Co Ltd?
Write Note

GemPharmatech Co Ltd
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

GemPharmatech Co Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
G
GemPharmatech Co Ltd
SSE:688046
Interest Income Expense
ÂĄ28.7m
CAGR 3-Years
65%
CAGR 5-Years
235%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Interest Income Expense
-ÂĄ570.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Interest Income Expense
ÂĄ540.1m
CAGR 3-Years
33%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Interest Income Expense
ÂĄ43.7m
CAGR 3-Years
-52%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Interest Income Expense
-ÂĄ101.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Interest Income Expense
ÂĄ2.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

GemPharmatech Co Ltd
Glance View

Market Cap
5.5B CNY
Industry
Life Sciences Tools & Services

GemPharmatech Co., Ltd. engages in research and development, manufacture, and sale of experimental mouse models. The company is headquartered in Nanjing, Jiangsu and currently employs 1,342 full-time employees. The company went IPO on 2022-04-25. The firm uses gene-editing and other technologies to produce mouse models. The firm also involves in the business of customized model breeding, drug efficacy analysis, and model customization. The Company’s products are mainly used to satisfy the experimental demands in the fields of gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental researches.

Intrinsic Value
21.04 CNY
Undervaluation 37%
Intrinsic Value
Price
G

See Also

What is GemPharmatech Co Ltd's Interest Income Expense?
Interest Income Expense
28.7m CNY

Based on the financial report for Dec 31, 2023, GemPharmatech Co Ltd's Interest Income Expense amounts to 28.7m CNY.

What is GemPharmatech Co Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
235%

Over the last year, the Interest Income Expense growth was 16%. The average annual Interest Income Expense growth rates for GemPharmatech Co Ltd have been 65% over the past three years , 235% over the past five years .

Back to Top